Skip to main content

Advertisement

SpringerLink
Log in

Serum carbohydrate antigen 125 is a significant prognostic marker in patients with unresectable advanced or recurrent gastric cancer

  • Original Article
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

Purpose

We evaluated the diagnostic and prognostic value of three tumor markers: carcino-embryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and carbohydrate antigen 125 (CA125), in the pretreatment serum of patients with unresectable advanced or recurrent gastric cancer.

Methods

The subjects of this retrospective analysis were 245 patients with unresectable advanced or recurrent gastric cancer diagnosed at Kochi Medical School between 2007 and 2015. We ascertained the sensitivity of CEA, CA19-9, and CA125 to identify a certain survival time and then evaluated the relative prognosis of the patients.

Results

The overall positive rates for each tumor marker in the study group were as follows: 57.6% (141/245) for CEA, 38.4% (94/245) for CA19-9, and 34.3% (84/245) for CA125; the sensitivity of these three biomarkers in combination was 73.1% (179/245). The median survival time of the CA125-positive patients was 4.5 months, which was significantly shorter than that of a normal range group (18.3 months, P < 0.001). Multivariate survival analysis identified that high CA125 was independently associated with a worse prognosis (HR 3.941; 95% CI 2.544–6.106; P < 0.001).

Conclusions

Pretreatment serum CA125 is a useful prognostic biomarker in patients with unresectable advanced or recurrent gastric cancer. Evaluating a panel of serum tumor biomarkers is a useful diagnostic tool as elevated values might be associated with poor survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.

    Article  PubMed  Google Scholar 

  2. Yamashita K, Miyazaki Y, Takahashi T, Masuike Y, Motoori M, Kimura Y, et al. Safety and feasibility of laparoscopic gastrectomy for gastric cancer patients with a history of abdominal surgery. Surg Today. 2017. doi:10.1007/s00595-017-1506-x.

    Google Scholar 

  3. Katayama H, Kurokawa Y, Nakamura K, Ito H, Kanemitsu Y, Masuda N, et al. Extended Clavien–Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria. Surg Today. 2016;46:668–85.

    Article  PubMed  Google Scholar 

  4. Shimada H, Noie T, Ohashi M, Oba K, Takahashi Y. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer. 2014;17:26–33.

    Article  CAS  PubMed  Google Scholar 

  5. Wada N, Kurokawa Y, Miyazaki Y, Makino T, Takahashi T, Yamasaki M, et al. The characteristics of the serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer cases. Surg Today. 2017;47:227–32.

    Article  CAS  PubMed  Google Scholar 

  6. Gold P. Freedman So. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med. 1965;121:439–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 1979;5:957–71.

    Article  CAS  PubMed  Google Scholar 

  8. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Investig. 1981;68:1331–7.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Jiexian J, Xiaoqin X, Lili D, Baoguo T, Ting S, Xianwen Z, Cunzhi H. Clinical assessment and prognostic evaluation of tumor markers in patients with gastric cancer. Int J Biol Markers. 2013;28:192–200.

    Article  PubMed  Google Scholar 

  10. Yamao T, Kai S, Kazami A, Koizumi K, Handa T, Takemoto N, et al. Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer. Jpn J Clin Oncol. 1999;29:550–5.

    Article  CAS  PubMed  Google Scholar 

  11. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.

    Article  CAS  PubMed  Google Scholar 

  12. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.

    Article  CAS  PubMed  Google Scholar 

  13. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009;10:1063–9.

    Article  CAS  PubMed  Google Scholar 

  14. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.

    Article  CAS  PubMed  Google Scholar 

  15. Namikawa T, Munekage E, Munekage M, Maeda H, Yatabe T, Kitagawa H, et al. Evaluation of a trastuzumab-containing treatment regimen for patients with unresectable advanced or recurrent gastric cancer. Mol Clin Oncol. 2016;5:74–8.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Sun Z, Zhang N. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy. World J Surg Oncol. 2014;12:397.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Maehara Y, Sugimachi K, Akagi M, Kakegawa T, Shimazu H, Tomita M. Serum carcinoembryonic antigen level increases correlate with tumor progression in patients with differentiated gastric carcinoma following noncurative resection. Cancer Res. 1990;50:3952–5.

    CAS  PubMed  Google Scholar 

  18. Kim DH, Yun HY, Ryu DH, Han HS, Han JH, Yoon SM, et al. Preoperative CA 125 is significant indicator of curative resection in gastric cancer patients. World J Gastroenterol. 2015;21:1216–21.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Wang Q, Yang Y, Zhang YP, Zou Z, Qian X, Liu B, et al. Prognostic value of carbohydrate tumor markers and inflammation-based markers in metastatic or recurrent gastric cancer. Med Oncol. 2014;31:289.

    Article  PubMed  Google Scholar 

  20. Wang W, Chen XL, Zhao SY, Xu YH, Zhang WH, Liu K, et al. Prognostic significance of preoperative serum CA125, CA19-9 and CEA in gastric carcinoma. Oncotarget. 2016;7:35423–36.

    PubMed  PubMed Central  Google Scholar 

  21. Kalniņa Z, Meistere I, Kikuste I, Tolmanis I, Zayakin P, Linē A. Emerging blood-based biomarkers for detection of gastric cancer. World J Gastroenterol. 2015;21:11636–53.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Chapman MA, Buckley D, Henson DB, Armitage NC. Preoperative carcinoembryonic antigen is related to tumour stage and long-term survival in colorectal cancer. Br J Cancer. 1998;78:1346–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Deng K, Yang L, Hu B, Wu H, Zhu H, Tang C. The prognostic significance of pretreatment serum CEA levels in gastric cancer: a meta-analysis including 14651 patients. PLoS One. 2015;10:e0124151.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Fan B, Xiong B. Investigation of serum tumor markers in the diagnosis of gastric cancer. Hepatogastroenterology. 2011;58:239–45.

    PubMed  Google Scholar 

  26. Kim DY, Kim HR, Shim JH, Park CS, Kim SK, Kim YJ. Significance of serum and tissue carcinoembryonic antigen for the prognosis of gastric carcinoma patients. J Surg Oncol. 2000;74:185–92.

    Article  CAS  PubMed  Google Scholar 

  27. Ikeda Y, Mori M, Adachi Y, Matsushima T, Sugimachi K, Saku M. Carcinoembryonic antigen (CEA) in stage IV gastric cancer as a risk factor for liver metastasis: a univariate and multivariate analysis. J Surg Oncol. 1993;53:235–8.

    Article  CAS  PubMed  Google Scholar 

  28. Kato Y, Takahashi S, Gotohda N, Konishi M. Prognostic impact of the initial postoperative CA19-9 level in patients with extrahepatic bile duct cancer. J Gastrointest Surg. 2016;20:1435–43.

    Article  PubMed  Google Scholar 

  29. Kodera Y, Yamamura Y, Torii A, Uesaka K, Hirai T, Yasui K, et al. The prognostic value of preoperative serum levels of CEA and CA19-9 in patients with gastric cancer. Am J Gastroenterol. 1996;91:49–53.

    CAS  PubMed  Google Scholar 

  30. Yu J, Zhang S, Zhao B. Differences and correlation of serum CEA, CA19-9 and CA72-4 in gastric cancer. Mol Clin Oncol. 2016;4:441–9.

    Article  PubMed  Google Scholar 

  31. Namikawa T, Fukudome I, Ogawa M, Munekage E, Munekage M, Shiga M, et al. Clinical efficacy of protein-bound polysaccharide K in patients with gastric cancer undergoing chemotherapy with an oral fluoropyrimidine (S-1). Eur J Surg Oncol. 2015;41:795–800.

    Article  CAS  PubMed  Google Scholar 

  32. Namikawa T, Munekage E, Munekage M, Maeda H, Yatabe T, Kitagawa H, et al. Evaluation of systemic inflammatory response biomarkers in patients receiving chemotherapy for unresectable and recurrent advanced gastric cancer. Oncology. 2016;90:321–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Kochi Medical School, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505, Japan

    Tsutomu Namikawa, Yasuhiro Kawanishi, Kazune Fujisawa, Eri Munekage, Jun Iwabu, Masaya Munekage, Hiroyuki Kitagawa & Kazuhiro Hanazaki

  2. Cancer Treatment Center, Kochi Medical School Hospital, Kochi, Japan

    Hiromichi Maeda & Michiya Kobayashi

  3. Department of Human Health and Medical Sciences, Kochi Medical School, Kochi, Japan

    Michiya Kobayashi

Authors
  1. Tsutomu Namikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yasuhiro Kawanishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kazune Fujisawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eri Munekage
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jun Iwabu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masaya Munekage
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiromichi Maeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hiroyuki Kitagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Michiya Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Kazuhiro Hanazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tsutomu Namikawa.

Ethics declarations

Conflict of interest

None of the authors received funding or have any competing interests to disclose.

Electronic supplementary material

Below is the link to the electronic supplementary material.

595_2017_1598_MOESM1_ESM.tif

Scatter plot of patient survival time against the value of tumor markers CEA (A), CA19-9 (B), and CA125 (C) (TIFF 5762 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Namikawa, T., Kawanishi, Y., Fujisawa, K. et al. Serum carbohydrate antigen 125 is a significant prognostic marker in patients with unresectable advanced or recurrent gastric cancer. Surg Today 48, 388–394 (2018). https://doi.org/10.1007/s00595-017-1598-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-017-1598-3

Keywords

Search

Navigation